Achieve Life Sciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACHV research report →
Companywww.achievelifesciences.com
Achieve Life Sciences, Inc. , a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
- CEO
- Richard A. Stewart
- IPO
- 1995
- Employees
- 25
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $246.14M
- P/E
- -4.73
- P/S
- 0.00
- P/B
- 23.04
- EV/EBITDA
- -4.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -193.49%
- ROIC
- -194.96%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-54,648,000 · -37.21%
- EPS
- $-1.25 · -0.81%
- Op Income
- $-54,880,000
- FCF YoY
- -66.17%
Performance & Tape
- 52W High
- $6.15
- 52W Low
- $2.00
- 50D MA
- $4.11
- 200D MA
- $4.07
- Beta
- 2.25
- Avg Volume
- 1.19M
Get TickerSpark's AI analysis on ACHV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Martin Christopher Nathan | other | 47,250 |
| May 11, 26 | Martin Christopher Nathan | other | 0 |
| Apr 17, 26 | Royston Aaron | other | 0 |
| Apr 17, 26 | TPG GP A, LLC | other | 0 |
| Apr 17, 26 | TPG GP A, LLC | other | 6,877,580 |
| Apr 17, 26 | Iancovici Lucian | other | 0 |
| Apr 18, 26 | Goldberg Andrew D. | other | 11,706,270 |
| Apr 18, 26 | Goldberg Andrew D. | other | 3,601,929 |
| Apr 18, 26 | Goldberg Andrew D. | other | 1,800,965 |
| Apr 18, 26 | Goldberg Andrew D. | other | 0 |
Our ACHV Coverage
We haven't published any research on ACHV yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACHV Report →